Trials
Search / Trial NCT06445088

Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma

Launched by SUN YAT-SEN UNIVERSITY · May 30, 2024

Trial Information

Current as of February 19, 2025

Recruiting

Keywords

Nasopharyngeal Carcinoma Diagnosis Methylation Detection Epstein Barr Virus

ClinConnect Summary

This clinical trial is studying a new test designed to help diagnose nasopharyngeal carcinoma, a type of cancer that affects the area behind the nose. The researchers want to see how well this test, which checks for specific changes in the Epstein-Barr virus (EBV) DNA, works in identifying this cancer. Participants will undergo various tests, including blood tests for EBV antibodies and a biopsy to confirm the diagnosis.

To join the study, participants should have symptoms that might suggest nasopharyngeal carcinoma and test positive for EBV-related markers. However, individuals who have already been treated for this cancer or have had a relapse cannot participate. If eligible, participants can expect a thorough evaluation involving swabs and tests, contributing to the understanding of this new diagnostic tool and potentially improving future cancer diagnosis.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants who meet the following Article 1 and also meet one of Articles 2 to 6 can be enrolled:
  • Understand, sign, and date the informed consent document to participate in the study
  • Display one or more symptoms or signs indicative of nasopharyngeal carcinoma
  • Test positive for EBV antibodies or EBV DNA
  • Be diagnosed with other head and neck carcinomas
  • Be diagnosed with malignancies associated with EBV infection
  • Require differential diagnosis from nasopharyngeal carcinoma during endoscopic or other imaging examinations
  • Fulfill any additional conditions deemed appropriate by the investigator for inclusion in this study
  • Exclusion Criteria:
  • Have been diagnosed with nasopharyngeal carcinoma and have undergone treatment
  • Experience relapse or metastasis of nasopharyngeal carcinoma following treatment
  • Have unsuccessful nasopharyngeal swab collections
  • Present any other conditions considered by the investigator as unsuitable for participation in this trial

Trial Officials

Hai-Qiang Mai

Study Chair

Sun Yat-sen University

Zhen-Zhou Xiao

Principal Investigator

Fujian Cancer Hospital

Min-Zhong Tang

Principal Investigator

Wuzhou Red Cross Hospital

Min-Yi Fu

Principal Investigator

Zhongshan People's Hospital, Guangdong, China

Zhe Zhang

Principal Investigator

First Affiliated Hospital of Guangxi Medical University

About Sun Yat Sen University

Sun Yat-sen University, a prestigious institution located in Guangzhou, China, is dedicated to advancing medical research and healthcare innovations. As a leading clinical trial sponsor, the university leverages its extensive academic resources and collaboration with top-tier medical professionals to conduct rigorous clinical studies. Committed to improving patient outcomes and contributing to global health knowledge, Sun Yat-sen University focuses on a wide range of therapeutic areas, employing cutting-edge methodologies to ensure the integrity and efficacy of its research initiatives. Through its clinical trials, the university aims to foster scientific advancements and enhance the quality of care provided to patients both locally and internationally.

Locations

Guangzhou, Guangdong, China

Nanning, Guangxi, China

Fuzhou, Fujian, China

Zhongshan, Guangdong, China

Wuzhou, Guangxi, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0